DK2733491T3 - Diagnostisk fremgangsmåde - Google Patents

Diagnostisk fremgangsmåde Download PDF

Info

Publication number
DK2733491T3
DK2733491T3 DK13194854.9T DK13194854T DK2733491T3 DK 2733491 T3 DK2733491 T3 DK 2733491T3 DK 13194854 T DK13194854 T DK 13194854T DK 2733491 T3 DK2733491 T3 DK 2733491T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
protein
disease
sequence
treatment
Prior art date
Application number
DK13194854.9T
Other languages
English (en)
Inventor
Thangue Nicholas B La
Susan Fotheringham
Original Assignee
Univ Oxford Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oxford Innovation Ltd filed Critical Univ Oxford Innovation Ltd
Application granted granted Critical
Publication of DK2733491T3 publication Critical patent/DK2733491T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01098—Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • C12N2330/31—Libraries, arrays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Claims (10)

1. Fremgangsmåde til diagnosticering af modtageligheden af et individ der lider af en sygdom overfor behandling med en HDAC-inhibitor, hvilken fremgangsmåde omfatter vurdering af ekspressionsniveauet eller aktivitet af et gen eller dets ekspressionsprodukter, eller sekvensen af et gen, i en vævsprøve fra en patient og sammenligne ekspressionsniveauet eller aktivitet eller sekvens med en reference, hvor ekspressionsniveauet eller aktivitet eller sekvens der er forskellig fra referencen er indikativ for en ændret modtagelighed for behandling med HDAC-inhibitoren i forhold til referencetilstanden, og hvor genet er Myd88 (myeloid differentiation primary response gene 88).
2. Fremgangsmåden ifølge krav 1, hvor et niveau der er signifikant højere end referenceniveauet indikerer at individet er mere modtagelig overfor behandling med en HDAC-inhibitor.
3. Fremgangsmåden ifølge krav 1, hvor et niveau der er signifikant lavere end referenceniveauet er indikation for et individs potentielle resistens for behandling med HDAC-inhibitoren.
4. Fremgangsmåden ifølge et hvilket som helst af de foregående krav, hvor ekspressionsproduktet er et protein, og hvor eventuelt fremgangsmåden omfatter trinnene at: (a) af bringe en ligand af proteinet i kontakt med en prøve fra en patient under betingelser der er egnede til dannelsen af et ligand-proteinkompleks; og (b) påvise komplekset.
5. Fremgangsmåden ifølge et hvilket som helst af kravene 1-3, hvor fremgangsmåden omfatter trinnene at: (a) isolere et nukleinsyremolekyle der koder for Myd88 fra en prøve fra en patient der er testet for sygdom; og (b) diagnosticere patienten ved påvisning af tilstedeværelsen afen mutation der er associeret med en ændret modtagelighed for behandling med HDAC-inhibitoren.
6. Anvendelsen af et array til diagnosticering af modtageligheden af et individ der lider af en sygdom for behandling med en HDAC-inhibitor ifølge et hvilket som helst af de foregående krav, hvor arrayet omfatter: (a) mindst to nukleinsyremolekyler, hvor hver af disse nukleinsyremolekyler svarer til sekvensen af; er komplementær med sekvensen af; eller hybridiserer specifikt til et nukleinsyremolekyle, hvor nukleinsyremolekylet: (i) omfatter sekvensen af Myd88 reciteret i accessionsnummer NM 002468; (ii) omfatter komplementet af (i); eller (iii) hybridiserer under højstringente betingelser til et nukleinsyremolekyle ifølge (i); eller (b) mindst to forskellige typer antistofspecier, hvor hver antistofspecie er immunospecifik med et protein hvor proteinet i (b): (iv) har en aminosyresekvens der kodes af en nukleinsyresekvens af (i)- (iii) ; eller (v) er et fragment af et protein ifølge (iv), forudsat at dette fragment bevarer den biologiske aktivitet der besiddes af fuldlængdepolypeptidet af (iv) ; eller har en antigen determinant fælles med polypeptidet af (iv).
7. En HDAC-inhibitor til anvendelse i behandling af en patient med en proliferativ sygdom eller en sygdom eller tilstand der involverer en ændring i celledifferentiering eller væksthastighed, hvor patienten er blevet identificeret som modtagelig for HDAC-inhibitorbehandling under anvendelse af fremgangsmåden ifølge et hvilket som helst af kravene 1 til 5, hvor den proliferative sygdom er cancer.
8. Anvendelsen af et antistof til diagnosticering af modtageligheden af et individ der lider afen sygdom for behandling med en HDAC-inhibitor ifølge fremgangsmåden ifølge et hvilket som helst af kravene 1-5, hvor antistoffet binder specifikt til et protein, hvor proteinet: (a) har en aminosyresekvens der kodes af en nukleinsyresekvens der: (i) omfatter sekvensen af Myd88 reciteret i accessionsnummer NM 002468; (ii) omfatter komplementet af (i); eller (iii) hybridiserer under højstringente betingelser til et nukleinsyremolekyle ifølge (i); eller (b) er et fragment af et protein ifølge (a), forudsat at dette fragment bevarer den biologiske aktivitet der besiddes af fuldlængdepolypeptidet af (a); eller har en antigen determinant fælles med polypeptidet af (a).
9. Anvendelse af et kit til diagnosticering af modtageligheden hos et individ der lider af en sygdom for behandling med en HDAC inhibitor, hvor kittet omfatter: (a) en første beholder indeholdende en nukleinsyreprobe der hybridiserer under stringente betingelser med et nukleinsyremolekyle, hvor nukleinsyremolekylet: (i) omfatter sekvensen af Myd88 reciteret i accessionsnummer NM 002468; (ii) omfatter komplementet af (i); eller (iii) hybridiserer under højstringente betingelser et nukleinsyremolekyle ifølge (i); (b) en anden beholder indeholdende primere der er anvendelige til amplificering af dette nukleinsyremolekyle; og (c) instruktioner til anvendelse af proben og primerne til at facilitere diagnosen; eller omfatter: (i) ét eller flere antistoffer ifølge krav 8; og (ii) et reagens der er anvendelig til påvisning af en bindingsreaktion mellem antistoffet og proteinet.
10. Fremgangsmåden ifølge et hvilket som helst af kravene 1 til 5, hvor vævsprøven, er blod, urin, spyt, eller en specifik vævsbiopsi.
DK13194854.9T 2006-03-27 2007-03-27 Diagnostisk fremgangsmåde DK2733491T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0606096.6A GB0606096D0 (en) 2006-03-27 2006-03-27 Screening method
EP11162743.6A EP2365335B1 (en) 2006-03-27 2007-03-27 Diagnostic method

Publications (1)

Publication Number Publication Date
DK2733491T3 true DK2733491T3 (da) 2017-01-09

Family

ID=36384256

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07732147.9T DK2005162T3 (da) 2006-03-27 2007-03-27 Screeningsmetode
DK13194854.9T DK2733491T3 (da) 2006-03-27 2007-03-27 Diagnostisk fremgangsmåde

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK07732147.9T DK2005162T3 (da) 2006-03-27 2007-03-27 Screeningsmetode

Country Status (8)

Country Link
US (3) US8784806B2 (da)
EP (3) EP2733491B1 (da)
JP (2) JP5528103B2 (da)
AT (1) ATE537445T1 (da)
DK (2) DK2005162T3 (da)
ES (3) ES2607753T3 (da)
GB (1) GB0606096D0 (da)
WO (1) WO2007110623A2 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005247943A1 (en) 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
EP2946810A1 (en) 2005-02-03 2015-11-25 TopoTarget UK Limited Combination therapy using an HDAC inhibitor and Vincristine for treating cancer
CN102579417B (zh) 2005-05-13 2014-11-26 托波塔吉特英国有限公司 Hdac抑制剂的药物制剂
EP2361619A1 (en) 2005-11-10 2011-08-31 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxd-101) alone for the treatment of hematological cancer
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method
CA2700173C (en) 2007-09-25 2016-10-11 Topotarget Uk Limited Methods of synthesis of certain hydroxamic acid compounds
CA2905377A1 (en) * 2013-03-11 2014-10-09 Pioneer Hi-Bred International, Inc. Methods and compositions to improve the spread of chemical signals in plants
GB201306339D0 (en) * 2013-04-08 2013-05-22 Isis Innovation Biomarkers for prognosis
GB2524519B (en) * 2014-03-25 2019-11-06 Pelago Bioscience AB Methods for identifying a biomarker indicative of a reduced drug response using a thermal shift assay
ES2702432B2 (es) 2017-08-31 2019-08-05 Venegas Pedro Manuel Medina Método y dispositivo para el análisis de ácidos nucleicos
GB201914517D0 (en) * 2019-10-08 2019-11-20 Randox Laboratories Ltd Xbp1 isoform multiplex assay
IL318095A (en) * 2022-07-27 2025-02-01 E Therapeutics Plc Double-stranded nucleic acid compounds that inhibit ZPI
CN116949169B (zh) * 2023-07-31 2024-02-06 山东大学齐鲁医院 Smek1在缺血性脑卒中诊治中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353891A1 (en) 2001-10-25 2003-05-06 Buck Institute For Age Research Screening system for modulators of her2 mediated transcription and her2 modulators identifed thereby
US20030186903A1 (en) * 2001-11-23 2003-10-02 Isis Pharmaceuticals Inc. Antisense modulation of MyD88 expression
JP2006505241A (ja) * 2002-02-08 2006-02-16 ノバルティス アクチエンゲゼルシャフト Ｈｄａｃ阻害活性を有する化合物のスクリーニング法
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
MXPA05005726A (es) * 2002-11-27 2005-08-16 Irm Llc Metodos y composiciones para inducir apoptosis en celulas de cancer.
EP1595952A4 (en) * 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
GB0401876D0 (en) * 2004-01-28 2004-03-03 Vereniging Het Nl Kanker I New use for cancer antigen
JP4761389B2 (ja) * 2004-04-09 2011-08-31 株式会社ジーンケア研究所 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤
AU2005233627A1 (en) * 2004-04-15 2005-10-27 Rosetta Inpharmatics Llc Methods for identifying genes that mediate a response of a living cell to an agent
EP1769242A2 (en) * 2004-07-19 2007-04-04 Schering Corporation Myd88 as a therapeutic target for cancer
CN102747141A (zh) * 2004-12-08 2012-10-24 安万特药物公司 测量对多西他赛抗药性或敏感性的方法
WO2007100650A2 (en) * 2006-02-23 2007-09-07 Yale University Drug resistance to plant alkaloids based upon myd88 status in a cell and methods of inhibiting signaling through the tlr-4:myd88 pathway
GB0606096D0 (en) 2006-03-27 2006-05-03 Cbmm Sa Screening method

Also Published As

Publication number Publication date
DK2005162T3 (da) 2012-03-05
EP2005162A2 (en) 2008-12-24
JP2013178260A (ja) 2013-09-09
EP2365335B1 (en) 2016-01-27
US9347103B2 (en) 2016-05-24
EP2365335A2 (en) 2011-09-14
WO2007110623A2 (en) 2007-10-04
JP5528103B2 (ja) 2014-06-25
US10012652B2 (en) 2018-07-03
US20140369999A1 (en) 2014-12-18
EP2005162B1 (en) 2011-12-14
ES2569663T3 (es) 2016-05-12
EP2733491B1 (en) 2016-09-21
US20170219594A1 (en) 2017-08-03
US8784806B2 (en) 2014-07-22
US20090311244A1 (en) 2009-12-17
GB0606096D0 (en) 2006-05-03
JP6017367B2 (ja) 2016-10-26
EP2365335A3 (en) 2011-12-28
EP2733491A1 (en) 2014-05-21
ATE537445T1 (de) 2011-12-15
JP2009531051A (ja) 2009-09-03
ES2607753T3 (es) 2017-04-03
WO2007110623A3 (en) 2008-12-04
ES2376912T3 (es) 2012-03-20

Similar Documents

Publication Publication Date Title
US10012652B2 (en) Screening method
Zhu et al. Impaired autophagic degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in gastric cancer
Ye et al. Arachidonic acid-regulated calcium signaling in T cells from patients with rheumatoid arthritis promotes synovial inflammation
Zhao et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer
Ma et al. USP1 inhibition destabilizes KPNA2 and suppresses breast cancer metastasis
Wang et al. Negative reciprocal regulation between Sirt1 and Per2 modulates the circadian clock and aging
Zhu et al. LMO1 synergizes with MYCN to promote neuroblastoma initiation and metastasis
Zhang et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
Geng et al. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein
Wang et al. METTL1/WDR4-mediated tRNA m7G modification and mRNA translation control promote oncogenesis and doxorubicin resistance
Yeh et al. MicroRNA‐138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF‐1α
Liu et al. Membrane-associated farnesylated UCH-L1 promotes α-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease
Adamson et al. OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas
Polytarchou et al. Akt2 regulates all Akt isoforms and promotes resistance to hypoxia through induction of miR-21 upon oxygen deprivation
Wang et al. Micro‐RNA‐30a regulates ischemia‐induced cell death by targeting heat shock protein HSPA5 in primary cultured cortical neurons and mouse brain after stroke
Lee et al. Cyclin D1–Cdk4 controls glucose metabolism independently of cell cycle progression
Ye et al. CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn’s disease
Xin et al. miR‐20b inhibits T cell proliferation and activation via NFAT signaling pathway in thymoma‐associated myasthenia gravis
Tao et al. PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation
Zhihua et al. p53‐induced long non‐coding RNA PGM5‐AS1 inhibits the progression of esophageal squamous cell carcinoma through regulating miR‐466/PTEN axis
Quan et al. USP39 Regulates NF-κB–mediated inflammatory responses through deubiquitinating K48-Linked IκBα
Paul et al. Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Cao et al. Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis
Gritti et al. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming
Yang et al. Abnormal mechanical stress induced chondrocyte senescence by yap loss‐mediated Mettl3 upregulation